CY1119311T1 - Ψευδο-πολυμορφικες μορφες καταστολεα πρωτεασης hiv - Google Patents

Ψευδο-πολυμορφικες μορφες καταστολεα πρωτεασης hiv

Info

Publication number
CY1119311T1
CY1119311T1 CY20171100896T CY171100896T CY1119311T1 CY 1119311 T1 CY1119311 T1 CY 1119311T1 CY 20171100896 T CY20171100896 T CY 20171100896T CY 171100896 T CY171100896 T CY 171100896T CY 1119311 T1 CY1119311 T1 CY 1119311T1
Authority
CY
Cyprus
Prior art keywords
pseudo
polymorphic forms
protease inhibitors
hiv protease
hydroxypropylcarbamate
Prior art date
Application number
CY20171100896T
Other languages
English (en)
Inventor
Hans Wim Pieter Vermeersch
Daniel Joseph Christiaan Thone
Luc Donné Marie-Louise Janssens
Piet Bert Paul Wigerinck
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119311(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of CY1119311T1 publication Critical patent/CY1119311T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Κοινοποιούνταν νέες ψευδό-πολυμορφικές μορφές του (3R,3aS,6aR)-hexahydrofuro [furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-l-benzyl-2-hydroxypropylcarbamate και διαδικασίες για την παρασκευή αυτών.
CY20171100896T 2002-05-16 2017-08-23 Ψευδο-πολυμορφικες μορφες καταστολεα πρωτεασης hiv CY1119311T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02076929 2002-05-16
EP03753571.3A EP1567529B2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor
EP14168686.5A EP2767539B1 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a HIV protease inhibitor

Publications (1)

Publication Number Publication Date
CY1119311T1 true CY1119311T1 (el) 2018-02-14

Family

ID=29724454

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20141100755T CY1115665T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY20141100756T CY1117928T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY20171100896T CY1119311T1 (el) 2002-05-16 2017-08-23 Ψευδο-πολυμορφικες μορφες καταστολεα πρωτεασης hiv

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20141100755T CY1115665T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY20141100756T CY1117928T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv

Country Status (26)

Country Link
US (8) US7700645B2 (el)
EP (4) EP1567529B2 (el)
JP (1) JP4864320B2 (el)
KR (2) KR20100119906A (el)
CN (1) CN100475819C (el)
AP (1) AP2052A (el)
AU (2) AU2003271740B2 (el)
BR (1) BRPI0311176B8 (el)
CA (1) CA2485834C (el)
CY (3) CY1115665T1 (el)
DK (3) DK2314591T4 (el)
EA (1) EA007120B8 (el)
ES (4) ES2503551T5 (el)
HK (1) HK1081969A1 (el)
HR (1) HRP20041061B1 (el)
HU (1) HUE034389T2 (el)
IL (1) IL165140A0 (el)
LT (1) LT2767539T (el)
MX (1) MXPA04011427A (el)
NO (1) NO331477B1 (el)
NZ (1) NZ536497A (el)
PL (1) PL215151B1 (el)
PT (3) PT1567529E (el)
SI (3) SI1567529T2 (el)
WO (1) WO2003106461A2 (el)
ZA (1) ZA200410154B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1088098T4 (en) 1998-06-23 2015-09-14 Us Of America Represented By The Secretary Dept Of Health And Human Services Fitnessassay and methods for reducing HIV resistance to therapy
US7700645B2 (en) * 2002-05-16 2010-04-20 Tibotec Pharmaceuticals Ltd. Pseudopolymorphic forms of a HIV protease inhibitor
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
US7772411B2 (en) 2003-12-23 2010-08-10 Tibotec Pharmaceuticals Ltd. Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
DE602006008751D1 (de) 2005-02-25 2009-10-08 Tibotec Pharm Ltd Synthese von proteaseinhibitorvorstufen
JP5491862B2 (ja) * 2006-11-09 2014-05-14 ヤンセン・アールアンドデイ・アイルランド ヘキサヒドロフロ［２，３−ｂ］フラン−３−オールの製造方法
TWI482775B (zh) 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備（３ｒ，３ａｓ，６ａｒ）－六氫呋喃并〔２，３－ｂ〕呋喃－３－基（１ｓ，２ｒ）－３－〔〔（４－胺基苯基）磺醯基〕（異丁基）胺基〕－１－苯甲基－２－羥基丙基胺基甲酸酯之方法
EP2381786B1 (en) * 2009-01-29 2014-12-24 Mapi Pharma Limited Dimethylsulfoxide solvate of darunavir
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
US8703980B2 (en) * 2009-09-17 2014-04-22 Siva Rama Prasad Vellanki Process for the preparation of darunavir
JP2013509400A (ja) * 2009-10-30 2013-03-14 ルパン リミテッド ダルナビルの新規調製方法および微粒子径のダルナビルエタノール付加物
CN102686594A (zh) * 2009-12-16 2012-09-19 熙德隆研究基金会 地瑞那韦的多晶型物
NZ600994A (en) * 2010-01-05 2014-04-30 Cipla Ltd Darunavir polymorph and process for preparation thereof
ES2516916T3 (es) 2010-01-28 2014-10-31 Mapi Pharma Limited Procedimiento para la preparación de darunavir e intermedios de darunavir
EP2571355B1 (en) 2010-05-20 2016-09-07 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
KR102058097B1 (ko) 2011-07-07 2019-12-20 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 다루나비어 복합 제제
WO2013114382A1 (en) 2011-12-05 2013-08-08 Mylan Laboratories Ltd Crystalline darunavir
US9643976B2 (en) * 2012-01-18 2017-05-09 Aurobindo Pharma Ltd. Solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
ES2848216T3 (es) 2012-07-24 2021-08-05 Laurus Labs Ltd Un proceso para la preparación de Darunavir
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
US9346820B2 (en) * 2013-09-11 2016-05-24 Purdue Research Foundation HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
WO2016092525A1 (en) * 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
EP3271347B1 (en) * 2015-03-19 2022-06-22 Mycovia Pharmaceuticals, Inc. Antifungal compounds and processes for making
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
EP3496719B1 (en) 2016-08-08 2023-06-14 Hetero Labs Limited A multi-class anti-retroviral composition
WO2018081292A1 (en) 2016-10-27 2018-05-03 Gilead Sciences, Inc. Crystalline forms of darunavir free base, hydrate, solvates and salts
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja) 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DK0715618T3 (da) * 1993-08-24 1999-08-23 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
KR100419355B1 (ko) 1995-02-22 2004-06-04 훽스트파마슈티칼스앤드케미칼스가부시키가이샤 무정형피레타나이드,피레타나이드다형체,이들의제조방법및이를포함하는약제학적조성물
CO4940492A1 (es) 1997-05-29 2000-07-24 Merck & Co Inc Inhibidor de proteasa de vih
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
DK1088098T4 (en) * 1998-06-23 2015-09-14 Us Of America Represented By The Secretary Dept Of Health And Human Services Fitnessassay and methods for reducing HIV resistance to therapy
AU1735000A (en) 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro-2(1h)-quinazolinone
PT1159278E (pt) 1999-02-12 2006-06-30 Vertex Pharma Inibidores de aspartil-protease
US7700645B2 (en) 2002-05-16 2010-04-20 Tibotec Pharmaceuticals Ltd. Pseudopolymorphic forms of a HIV protease inhibitor
NZ600994A (en) * 2010-01-05 2014-04-30 Cipla Ltd Darunavir polymorph and process for preparation thereof

Also Published As

Publication number Publication date
ES2503551T3 (es) 2014-10-07
HUE034389T2 (en) 2018-02-28
AP2052A (en) 2009-10-05
NO20045409L (no) 2004-12-10
EA007120B1 (ru) 2006-06-30
EP1567529B2 (en) 2021-02-24
BRPI0311176B8 (pt) 2021-05-25
SI2314591T1 (sl) 2014-11-28
CN100475819C (zh) 2009-04-08
NO331477B1 (no) 2012-01-16
PL374321A1 (en) 2005-10-17
SI1567529T1 (sl) 2014-11-28
CY1115665T1 (el) 2017-01-25
EP2314591B2 (en) 2021-02-24
AU2003271740A1 (en) 2003-12-31
ES2498370T5 (es) 2021-11-24
AU2012205289A1 (en) 2012-08-09
ES2498370T3 (es) 2014-09-24
SI2767539T1 (sl) 2017-10-30
HRP20041061A2 (en) 2006-07-31
PT2767539T (pt) 2017-08-28
US20150336980A1 (en) 2015-11-26
WO2003106461A2 (en) 2003-12-24
WO2003106461A3 (en) 2004-05-13
DK1567529T3 (da) 2014-09-15
CA2485834C (en) 2007-07-17
EP2767539A1 (en) 2014-08-20
US7700645B2 (en) 2010-04-20
DK2314591T3 (da) 2014-09-22
US20210179631A1 (en) 2021-06-17
LT2767539T (lt) 2017-09-25
PT2314591E (pt) 2014-09-19
PT1567529E (pt) 2014-09-09
EP3045460A1 (en) 2016-07-20
US20170260196A1 (en) 2017-09-14
EA007120B8 (ru) 2012-03-30
EP1567529A2 (en) 2005-08-31
IL165140A0 (en) 2005-12-18
HK1081969A1 (en) 2006-05-26
JP2005533068A (ja) 2005-11-04
PL215151B1 (pl) 2013-10-31
DK2767539T3 (en) 2017-09-11
DK2314591T4 (da) 2021-05-10
SI1567529T2 (sl) 2021-08-31
ES2638412T3 (es) 2017-10-20
US20180312517A1 (en) 2018-11-01
EP2314591A1 (en) 2011-04-27
MXPA04011427A (es) 2005-02-17
US10000504B2 (en) 2018-06-19
BRPI0311176B1 (pt) 2019-08-20
EP1567529B1 (en) 2014-06-18
US20100204316A1 (en) 2010-08-12
DK1567529T4 (da) 2021-05-10
CY1117928T1 (el) 2017-05-17
JP4864320B2 (ja) 2012-02-01
NZ536497A (en) 2006-08-31
EP3045460B1 (en) 2019-04-17
US20140171499A1 (en) 2014-06-19
US8518987B2 (en) 2013-08-27
EP2767539B1 (en) 2017-07-12
AU2003271740B2 (en) 2010-05-13
KR101128370B1 (ko) 2012-04-23
BR0311176A (pt) 2005-03-15
KR20050008715A (ko) 2005-01-21
ES2503551T5 (es) 2021-10-28
SI2314591T2 (sl) 2021-08-31
EA200401503A1 (ru) 2005-06-30
US10858369B2 (en) 2020-12-08
ES2728735T3 (es) 2019-10-28
AP2004003191A0 (en) 2004-12-31
US20130303790A1 (en) 2013-11-14
CN1668623A (zh) 2005-09-14
KR20100119906A (ko) 2010-11-11
CA2485834A1 (en) 2003-12-24
ZA200410154B (en) 2005-12-28
HRP20041061B1 (hr) 2015-02-27
EP2314591B1 (en) 2014-06-18
US20050250845A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
CY1119311T1 (el) Ψευδο-πολυμορφικες μορφες καταστολεα πρωτεασης hiv
CY1109379T1 (el) Διεργασια για την παρασκευη (3r,3αs,6αr)-εξαϋδροφουρο [2,3-β] φουραν-3-υλ (1s,2r)-3-[[(4-αμινοφαινυλ) σουλφονυλ] (ισοβουτυλ) αμινο]-1-βενζυλ-2-υδροξυπροπυλκαρβαμικου
UA85567C2 (en) Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
DK1343782T3 (da) Pyrimidinaminer som angiogenesemodulatorer
EA200100053A1 (ru) Кальций (3s)тетрагидро-3-фуранил(1s,2r)-3-[[(4-аминофенил)сульфонил](изобутил)амино]-1-бензил-2-(фосфоноокси)пропилкарбамат
HUP0402029A2 (hu) Peptidalapú multimer célzott kontrasztanyagok
BR0209984A (pt) Processo para a preparação de prostaglandinas e seus análogos
AR053270A1 (es) Sistema de lentes de contacto hibridas y metodo de ajuste
WO2005120166A3 (en) Antibodies for selective apoptosis of cells
DK2089371T3 (da) Fremstillingsmåde til fremstilling af hexahydrofuro[2,3-b]furan-3-OL
EA200700355A1 (ru) Вибродатчик
BRPI0917377A2 (pt) processo para a preparacao de (1s,2r)-3-[[(4-aminofenil) sulfonil] (isobutil) amino]-1-benzil-2-hidroxipropilcarbamato de (3r,3as,6ar)-hexahidrofuro[2,3-b] furan-3-ila
CY1105856T1 (el) ΠΑΡΑΣΚΕΥΗ ΤΩΝ ΣΤEPΕΟΪΣΟΜEPΩΝ ΤΗΣ (3ΑΛΦΑ, 3ΑΛΦΑ/ΒΗΤΑ, 6ΑΛΦΑ/ΒΗΤΑ) ΕΞΑΫΔΡΟΦΟΥΡΟ [2,3-b] ΦΟΥΡΑΝ-3-ΟΛΗΣ
DK1436278T3 (da) Fremgangsmåde til fremstilling af 14-beta-hydroxy-baccatin-III-1,14-carbonat
ATE443243T1 (de) Laserkreisel mit ringförmigen aussparungen
WO2004091280A3 (en) Pharmaceutical compositions
UY26643A1 (es) Producto farmacéutico cristalino
ITMI20011731A0 (it) Oricedimento per la preparazione del \4beta-idrosasi-baccatina iii-1,14-carbonato
ITMI20011735A0 (it) Procedimento per la preparazione del 14beta-idrossi-baccatina iii-1,14-carbonato
UA6493S (uk) Ковпачок до флаконів (комбінований)